Published in Biochem J on August 15, 2012
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A (2014) 1.53
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front Mol Neurosci (2014) 1.03
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol (2014) 0.96
Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. EMBO J (2014) 0.96
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J (2013) 0.94
Heat shock proteins in neurodegenerative disorders and aging. J Cell Commun Signal (2014) 0.93
Cellular effects of LRRK2 mutations. Biochem Soc Trans (2012) 0.90
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci (2014) 0.89
LRRK2: cause, risk, and mechanism. J Parkinsons Dis (2013) 0.88
Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7. Nat Commun (2014) 0.87
Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun (2013) 0.87
Cellular processes associated with LRRK2 function and dysfunction. FEBS J (2015) 0.86
Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum Mol Genet (2014) 0.86
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front Mol Neurosci (2014) 0.85
LRRK2: an éminence grise of Wnt-mediated neurogenesis? Front Cell Neurosci (2013) 0.83
Genetic variants ofLRRK2 in Taiwanese Parkinson's disease. PLoS One (2013) 0.83
Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution. J Biol Chem (2014) 0.82
GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1. Sci Rep (2012) 0.81
A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease. Parkinsons Dis (2012) 0.80
The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem J (2016) 0.79
Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. PLoS One (2014) 0.78
The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies. Neurol Sci (2014) 0.77
Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. Front Mol Neurosci (2016) 0.76
G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. Biomed Res Int (2016) 0.75
Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations. PLoS One (2016) 0.75
The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Sci Rep (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet (2006) 4.61
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci (2006) 3.58
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64
Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry (2010) 1.47
Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem (2009) 1.42
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
The WD40 domain is required for LRRK2 neurotoxicity. PLoS One (2009) 1.32
Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport (2007) 1.23
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med (2012) 1.10
Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One (2009) 1.07
Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord (2011) 1.07
Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol (2009) 1.03
Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord (2009) 1.01
Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem J (2012) 0.99
The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta (2009) 0.98
A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol (2006) 0.96
Mechanism of kinase inactivation and nonbinding of FRATide to GSK3β due to K85M mutation: molecular dynamics simulation and normal mode analysis. Biopolymers (2011) 0.83
Structural and functional consequences of the substitution of glycine 65 with arginine in the N-lobe of human transferrin. Biochemistry (2009) 0.81
The substitution of glycine 661 by arginine in type III collagen produces mutant molecules with different thermal stabilities and causes Ehlers-Danlos syndrome type IV. J Med Genet (1993) 0.81
Impact of inter-subunit interactions on the dimeric arginine kinase activity and structural stability. Arch Biochem Biophys (2011) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol (2010) 11.85
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A (2004) 4.76
Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A (2005) 4.22
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy (2010) 3.68
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Genetics of Parkinson's disease and parkinsonism. Ann Neurol (2006) 3.60
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2010) 3.00
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet (2007) 2.84
The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem (2008) 2.77
RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A (2008) 2.76
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A (2008) 2.64
Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet (2011) 2.62
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci (2002) 2.54
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38
Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A (2008) 2.36
Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol (2008) 2.34
Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci U S A (2010) 2.33
Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One (2009) 2.23
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A (2011) 2.15
L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem (2003) 2.12
Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet (2007) 2.09
Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol (2010) 2.08
A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet (2009) 1.93
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis (2006) 1.83
Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem (2009) 1.71
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem (2007) 1.70
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J (2008) 1.68
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun (2009) 1.67
Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol (2004) 1.67
Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron (2004) 1.64
Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons. Cell Cycle (2012) 1.62
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A (2014) 1.53
Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain (2002) 1.43
Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Hum Genet (2010) 1.42
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Vaccinia virus G7L protein Interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J Virol (2003) 1.39
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One (2010) 1.39
Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J Biol Chem (2003) 1.38
EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood (2009) 1.38
SUMOylation participates in induction of ischemic tolerance. J Neurochem (2009) 1.38
Genome-wide compensatory changes accompany drug- selected mutations in the Plasmodium falciparum crt gene. PLoS One (2008) 1.36
Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis (2012) 1.35
cDNA sequences reveal considerable gene prediction inaccuracy in the Plasmodium falciparum genome. BMC Genomics (2007) 1.35
Exome sequencing in an SCA14 family demonstrates its utility in diagnosing heterogeneous diseases. Neurology (2012) 1.33
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
Identification of a novel oligodendrocyte cell adhesion protein using gene expression profiling. J Neurosci (2006) 1.32
Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem (2003) 1.32
mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. Nat Neurosci (2013) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A (2009) 1.28
Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One (2011) 1.28
Canonical transient receptor potential 1 plays a role in basic fibroblast growth factor (bFGF)/FGF receptor-1-induced Ca2+ entry and embryonic rat neural stem cell proliferation. J Neurosci (2005) 1.27
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood (2008) 1.27
Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol (2009) 1.27
Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res (2013) 1.25
Reelin and stk25 have opposing roles in neuronal polarization and dendritic Golgi deployment. Cell (2010) 1.25
Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol (2004) 1.24
An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis Model Mech (2009) 1.22